Compare AU
Compare MQDB vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are MQDB and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
MQDB | DRUG | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 63 |
Median incremental investment | $0 | $967.00 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,875.72 |
Average age group | N/A | 26 - 35 |
Key Summary
MQDB | DRUG | |
|---|---|---|
Strategy | MQDB.AX was created on 2002-09-30 by Macquarie. The fund's investment portfolio concentrates primarily on broad credit fixed income. The Fund aims to generate attractive returns by dynamically investing in global fixed income instruments. It aims to provide diversification against equity risk as well as capital growth and some income | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Macquarie Dynamic Bond Active ETF (Managed Fund) (100 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.614 % | 0.57 % |
Key Summary
MQDB | DRUG | |
|---|---|---|
Issuer | Macquarie | BetaShares |
Tracking index | Bloomberg Global Aggregate Index - AUD - Benchmark TR Net Hedged | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.614 % | 0.57 % |
Price | $10.78 | $8.12 |
Size | N/A | $191.120 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | 0.12 % | 1.90 % |
Market | ASX | ASX |
First listed date | 21/11/2023 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
MQDB | DRUG | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 63 |
Median incremental investment | $0 | $967.00 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,875.72 |
Average age group | N/A | 26 - 35 |
Pros and Cons
MQDB | DRUG | |
|---|---|---|
Pros |
| |
Cons |
|
MQDB | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |